GFAP and Alzheimer disease: Comparison of cortex and serum led to an AD-correlated protein panel of CTHRC1, GFAP and OLFM3.104 The CAMKK2-AMPK kinase pathway mediates the early synaptic toxic effects of Aβ42 oligomers and is a target for AD therapeutics 105.